Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Pulmonary Arterial Hypertension
NCT03782818Phase 2Terminated
- Sponsor
- Université Laval
- Start
- Nov 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in pulmonary arterial hypertension (PAH), sponsored by Université Laval. Started Nov 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03782818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782818.